Latest News
-
Wednesday - August 28, 2019
Bayer Animal Health launches Drontal™ Plus Tasty in China
Since its launch in China 10 years ago Drontal has a leading position in the veterinary channel / Drontal™ Plus Tasty replaces Drontal™ Plus Flavor with new innovative key features » more
-
Tuesday - August 20, 2019
Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollars
Exit of Animal Health business completes the series of portfolio measures initiated by Bayer in November 2018 ahead of announced schedule / Enhances Bayer’s focus as a global leader in life sciences » more
-
Thursday - August 15, 2019
Bayer provides produce growers with holistic approach to field challenges during first ever Agriculture and Innovation Showcase
De Ruiter and Seminis seed brands discuss sustainable and tailored solutions / Industry collaborators demonstrate new advances in digital automation technology » more
-
Thursday - August 8, 2019
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year / BlueRock Therapeutics to continue to operate as an independent company » more
-
Tuesday - August 6, 2019
Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real Assets
Currenta valued with an attractive enterprise value of EUR 3.5 billion (100%) » more
-
Wednesday - July 31, 2019
Not intended for U.S. and UK Media
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer
Darolutamide was approved in the U.S. under the FDA Priority Review designation; approval granted three months ahead of target FDA action date / Approval based on Phase III ARAMIS trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT » more
-
Tuesday - July 30, 2019
Second quarter of 2019:
Bayer on track in operational business
Group sales increase by 0.9 percent (Fx & portfolio adj.) to 11.485 billion euros / EBITDA before special items advances by 24.7 percent to 2.927 billion euros / Crop Science sees sales decline (Fx & portfolio adj. and pro forma) in challenging environment but posts substantial earnings growth due to acquired business / Pharmaceuticals posts higher sales and strong earnings growth / Consumer Health increases sales and earnings / Net income falls by 49.1 percent to 404 million euros, held back by special items for restructuring and impairments / Core earnings per share increase by 5.9 percent to 1.62 euros / Group outlook confirmed yet increasingly ambitious » more
-
Friday - July 26, 2019
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in Europe
Recommendation for approval for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Upon approval, larotrectinib would be the first therapy in Europe with a tumor-agnostic indication / CHMP opinion is based on pooled data showing that larotrectinib provides high and durable responses in adult and pediatric patients with TRK fusion cancer, including CNS tumors / Larotrectinib showed a favorable safety profile, with the majority of adverse events being grade 1 or 2 / Final decision from the European Commission is anticipated within the next months » more
-
Wednesday - July 24, 2019
Bayer and White Ribbon Alliance announce three-year renewal of partnership to improve the every day health of women, infants and children through self-care
Bayer and White Ribbon Alliance efforts have engaged more than 90 communities to take self-care actions and increase utilization of vital health services » more
-
Monday - July 22, 2019
Yellow Wood Partners to acquire iconic Dr. Scholl’s™ brand from Bayer » more
-
Thursday - July 18, 2019
Not intended for U.S. and UK Media
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga™ (regorafenib) and Opdivo™ (nivolumab) as combination therapy in patients with colorectal cancer
Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer / Companies plan indication-seeking trial » more
-
Wednesday - July 17, 2019
Pyxis Oncology Founded by Longwood Fund with Financing Led by Bayer
Building on New Insights in Tumor Biology Discovered by Award-winning Cancer Researcher Thomas Gajewski, MD, PhD / USD 22 Million Series A to Fund Pipeline of Antibodies Focused on Novel Immuno-oncology Targets » more
-
Monday - July 15, 2019
Not intended for U.S. and UK Media - Magnetic Resonance Imaging (MRI):
FDA approves Bayer's Gadavist™ as first and only contrast agent for use in cardiac MRI in patients with coronary artery disease » more
-
Thursday - July 11, 2019
Talent Awards from the Bayer Science & Education Foundation:
New winners of Bayer Early Excellence in Science Award: EUR 30,000 for international research scientists
Dr. Julian Stingele (Ludwig-Maximilians-University, Munich, Germany) wins the „Biology“ category / Dr. Christina Woo (Harvard University, Boston, MA, USA) takes the „Chemistry“ award / Dr. Susanne van Veluw (Harvard Medical School, MA, USA) awarded prize in the „Medical Science“ field » more
-
Wednesday - July 10, 2019
Bayer Trendlines Ag Innovation Fund to co-invest with Trendlines in new company
Novel technology licensed from the Weizmann Institute of Science for biological solutions to treat bacterial diseases in crops » more
-
Monday - July 8, 2019
Not intended for U.S. and UK Media - Important step towards improved treatment for children with venous thromboembolism
Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolism
Phase III EINSTEIN-Jr. study in children concludes the largest pediatric thromboembolism program delivering results consistent with those in adults / Study shows a low risk of recurrent venous thromboembolism (VTE) in children treated with rivaroxaban compared with standard of care with low rates of bleeding / First phase III data on the use of a non-vitamin K oral anticoagulant (NOAC) in a large pediatric population / Study investigated a body weight-adjusted oral 20 mg equivalent dose of rivaroxaban for the prevention of recurrent VTE in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis » more
-
Wednesday - July 3, 2019
Prestigious award from the Bayer Science & Education Foundation:
2019 Hansen Family Award goes to Professor Edith Heard
Professor Edith Heard, Director General of the European Molecular Biology Laboratory (EMBL) is awarded for groundbreaking insights into the field of epigenetics and its role in basic medical research » more
-
Tuesday - July 2, 2019
Data-Driven Tools from The Climate Corporation’s Climate FieldView™ Platform Now Available for Argentine Farmers:
Bayer expands industry-leading digital farming platform in Argentina » more
-
Tuesday - July 2, 2019
Not intended for U.S. Media
Bayer’s new SRD Smart Compare aids responsible antibiotic use in swine respiratory disease treatment
Novel online comparison tool puts solid efficacy data on swine respiratory treatments at veterinarians’ fingertips » more
-
Tuesday - July 2, 2019
LEO Pharma completes the acquisition of Bayer’s prescription dermatology business » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
Bayer TV